US equities |
MU $928.76 ▲+0.00% SNDK $1,304.84 ▲+0.00% SKHY $145.36 ▲+0.00% TSLA $407.46 ▲+0.00% NVDA $217.94 ▲+0.00% INTC $93.74 ▲+0.00% SPCX $148.58 ▲+0.00% STX $667.85 ▲+0.00%
FinancialContent

Nyxoah SA - Ordinary Shares (NQ:NYXH)

0.9108 UNCHANGED
Delayed Quote Updated: 3:59 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nyxoah SA - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Information on the total number of voting rights and shares
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah Q1 Earnings Call Highlights ↗
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the... 
Via MarketBeat
Topics Earnings
News headline image
Nyxoah Reports First Quarter 2026 Financial and Operating Results
From Nyxoah
Via GlobeNewswire
News headline image
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 10, 2026
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah to Participate in the Bank of America 2026 Healthcare Conference
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026
From Nyxoah
Via GlobeNewswire
News headline image
Publication relating to transparency notifications
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript ↗
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
From Nyxoah
Via GlobeNewswire
News headline image
Publication relating to transparency notification
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
From Nyxoah
Via GlobeNewswire
News headline image
Publication relating to transparency notifications
From Nyxoah
Via GlobeNewswire
News headline image
Information on the total number of voting rights and shares
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
From Nyxoah
Via GlobeNewswire
News headline image
Publication relating to transparency notification
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah SA (NASDAQ: NYXH): A Deep Dive into its Bilateral Approach to Sleep Apnea
Nyxoah SA (NASDAQ: NYXH; Euronext Brussels: NYXH) is a Belgium-based medical technology company making significant strides in the treatment of Obstructive Sleep Apnea (OSA). The company is currently in... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
From Nyxoah
Via GlobeNewswire
News headline image
Publication relating to transparency notifications
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy ↗
Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions. 
Via Stocktwits
News headline image
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
From Nyxoah
Via GlobeNewswire
News headline image
Information on the total number of voting rights and shares
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
From Nyxoah
Via GlobeNewswire
News headline image
Nyxoah (NYXH) Q3 2025 Earnings Call Transcript ↗
Nyxoah (NYXH) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Bonds Earnings Economy
News headline image
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
From Nyxoah
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >